hi

Myelodysplastic Syndrome (MDS) Drugs Market 2021 Industry Challenges, Top Manufacturers, Key Countries with Forecast to 2030 | Says Kenneth Research

In a recent published report, Kenneth Research has updated the market report for Myelodysplastic Syndrome (MDS) Drugs Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In the view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to be regain 25% by the end of 2021- Positive Growth in the economic demand and supply.  

U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4  billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Myelodysplastic Syndrome (MDS) Drugs Market products.  

The Myelodysplastic Syndrome (MDS) Drugs Market is thriving on account of the rising awareness amongst individuals for the benefits of maintaining a good health and the increasing need for high quality healthcare services amongst individuals. With the increasing prevalence of diseases worldwide, people are opting for products that help them to stay fit and are also investing more on healthcare services. Alternatively, pharmaceutical manufacturers, along with other healthcare companies that manufactures devices and equipment, are increasingly focusing on the research and development of advanced treatment, drugs and equipment for the diagnosis and treatment of the diseases and for developing healthcare products. Organizations are raising their R&D expenses year-on-year so as to deliver quality healthcare products in the years to come. The advancements in the healthcare sector are also supported by the governments of nations worldwide with numerous financial aids. According to a statistical report titled “Global Spending on Health: A World in Transition”, released in theyear 2019 by the World Health Organization (WHO), the global spending on healthcare recorded USD 7.8 trillion in 2017, which was an increase by USD 0.2 trillion from the recorded value of USD 7.6 trillion in 2016.

Market Scenario

The global myelodysplastic syndrome (MDS) drugs market is expected to grow significantly over the forecast period. It is anticipated that the market held a value of USD 1,581.59 million in 2018 and is projected to register a CAGR of 10.1% over the forecast period.The increasing participation of key players is one of the key factors driving the Myelodysplastic Syndrome (MDS) drugs market. In 2018, the US Food and Drug Administration approved a generic injectable product, decitabine for Lupin Ltd. There are various other MDS medications available in the market.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159221

Various other factors such as the promotion of clinical studies related to MS, increasing geriatric population, rise in regulatory approvals, and growing participation of generic drug manufacturers are boosting the market growth.However, the risk of infections during blood transfusions and side-effects of chemotherapy may hamper market growth over the forecast period.

Segmentation

The global myelodysplastic syndrome (MDS) drugs market is segmented based on type, type of syndrome, route of administration, end user, and region.Based on type, the global myelodysplastic syndrome (MDS) drugs market is further segmented into chemotherapy, immunomodulatory drugs, and others. The chemotherapy segment is sub-segmented as conventional drugs and hypomethylating drugs. Hypomethylating drugs include Azacitidine and Decitabine. Conventional drugs comprise Cytarabine, Daunorubicin, and Idarubicin.Based on the type of syndrome, the MDS drugs market at the global level is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia, refractory anemia with excess blasts,  refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and others.

Based on the route of administration, the market is segmented into oral, parenteral, and others.Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others.The segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.The myelodysplastic syndrome (MDS) drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Myelodysplastic Syndrome (MDS) drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Myelodysplastic Syndrome (MDS) drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The myelodysplastic syndrome drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159221

Key Players

BluePoint Laboratories
Celgene Corporation
Celgene Europe Limited
Reddy’s Laboratories, Inc.
Johnson & Johnson
Lupin Ltd Corporation
Otsuka America Pharmaceutical Inc.
Sandoz
Shilpa Medicare Limited
Sun Pharmaceutical Industries Inc.
Regional Market Summary

The Americas dominated the global MDS drugs market, owing to the increasing number of patients detected with MDS yearly. According to the statistics published by the American Society of Clinical Oncology in 2019, around 10,000 patients are detected with MDS in the US yearly.In the European region, various studies have been performed to study the prevalence of MDS across different age groups. For instance, the National Institutes of Health conducted a successive study among children with MDS for 15 years. Under the study, 426 children were investigated for Germline GATA-2 mutations and primary MDS. The studies revealed that Germline GATA-2 mutations highly prevailed in patients with monosomy 7 type of mutation. Thus, the European region has a potential scope for the MDS drugs market.

Asia-Pacific is expected to grow owing to the rising research and development activities in this region.  The study of clinical features is very important before proceeding for treatment methodology for a patient. As per the study published in the Leukemia Journal in 2018, the difference in clinical features among the Japanese and Caucasian patients with myelodysplastic syndromes was noticed. The study revealed that; chronic lymphocytic leukemia is more frequent in the Caucasians population than the Japanese population. This could be due to susceptibility specific location of the genome. Thus, the MDS drugs market in APAC is predicted to gain the third-largest market share.The Middle East and Africa held the least share in the global myelodysplastic syndrome (MDS) drugs market due to low economic development, especially within the African region.

Request For Full Report- https://www.kennethresearch.com/sample-request-10159221

Intended Audience

Pharmaceutical companies
Government and private laboratories
Research and development (R&D) companies
Research laboratories
Market research and consulting service providers
Market Segmentation

Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type

Chemotherapy
Hypomethylating Drugs
Azacitidine
Decitabine
Conventional drugs
Cytarabine
Daunorubicin
Idarubicin
Immunomodulatory Drugs
Lenalidomide
Thalidomide
Others
Global Myelodysplastic Syndrome (MDS) Drugs Market, by Type of Syndrome

Refractory Anemia
Refractory Anemia with Ringed Sideroblasts
Refractory Anemia with Excess Blasts
Refractory Cytopenia with Multilineage Dysplasia
Others
Global Myelodysplastic Syndrome (MDS) Drugs Market, by Route of Administration

Oral
Parenteral
Others
Global M

Darlene Dooley is a research expert and freelance writer. She is very dedicated towards her work and writing. She enjoys to write on current news on any industry and conclude the news with highly professional report. She has almost 8 years of experience in the same field. She has strong professional skill in Market research, Business Strategies, online marketing, Industry analysis interested in innovative and trending technologies.

Leave a Reply